CA2917742C - A pharmaceutical combination for the treatment of melanoma - Google Patents

A pharmaceutical combination for the treatment of melanoma Download PDF

Info

Publication number
CA2917742C
CA2917742C CA2917742A CA2917742A CA2917742C CA 2917742 C CA2917742 C CA 2917742C CA 2917742 A CA2917742 A CA 2917742A CA 2917742 A CA2917742 A CA 2917742A CA 2917742 C CA2917742 C CA 2917742C
Authority
CA
Canada
Prior art keywords
inhibitor
melanoma
compound
braf
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2917742A
Other languages
English (en)
French (fr)
Other versions
CA2917742A1 (en
Inventor
Veena Agarwal
Giridharan Periyasamy
Maggie Rathos
Ankita SRIVASTAVA
Sreesha SRINIVASA
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of CA2917742A1 publication Critical patent/CA2917742A1/en
Application granted granted Critical
Publication of CA2917742C publication Critical patent/CA2917742C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2917742A 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma Active CA2917742C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845749P 2013-07-12 2013-07-12
US61/845,749 2013-07-12
PCT/IB2014/063022 WO2015004636A1 (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Publications (2)

Publication Number Publication Date
CA2917742A1 CA2917742A1 (en) 2015-01-15
CA2917742C true CA2917742C (en) 2020-04-14

Family

ID=52279411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917742A Active CA2917742C (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Country Status (12)

Country Link
US (4) US11007174B2 (enExample)
EP (1) EP3019166B1 (enExample)
JP (5) JP6568060B2 (enExample)
CN (3) CN105530931B (enExample)
AR (1) AR096892A1 (enExample)
AU (1) AU2014288857B2 (enExample)
CA (1) CA2917742C (enExample)
DK (1) DK3019166T3 (enExample)
ES (1) ES2733929T3 (enExample)
IL (1) IL243572B (enExample)
TW (4) TWI839690B (enExample)
WO (1) WO2015004636A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
CN117257802A (zh) 2015-06-05 2023-12-22 伊利诺伊大学董事会 Pac-1联合疗法
EP3881833B1 (en) * 2015-06-30 2023-11-01 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
WO2017160983A1 (en) * 2016-03-16 2017-09-21 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
MX2020004991A (es) 2017-11-17 2022-02-10 Univ Illinois Terapia oncológica mediante la degradación de la señalización dual de mek.
CN107827726B (zh) * 2017-11-28 2020-09-15 辽宁中医药大学 马齿苋中化合物Oleracone E及其提取分离方法
CN108591464B (zh) * 2018-06-28 2020-06-23 宁波奥克斯高科技有限公司 一种气体绝缘开关柜用密封结构
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
KR20220023333A (ko) * 2019-04-11 2022-03-02 메이 파마, 아이엔씨. 보루시클립 다형체 및 그의 제조 및 사용 방법
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合
CN112168821B (zh) * 2020-11-09 2022-10-14 中南大学湘雅医院 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
EP4247806A4 (en) * 2020-11-19 2024-11-13 MEI Pharma, Inc. TREATMENT OF KRAS-MUTANT CANCERS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
WO2001083469A1 (en) 2000-05-03 2001-11-08 Lg Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
US6699997B2 (en) 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
MXPA05004919A (es) 2002-11-06 2005-08-18 Cyclacel Ltd Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
MXPA06006291A (es) 2003-12-08 2006-08-23 Univ Arizona Composiciones anti-cancer sinergisticas.
WO2006099193A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
PL2395004T3 (pl) * 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
MX2008016398A (es) 2006-06-21 2009-01-21 Piramal Life Sciences Ltd Compuestos enantiomericamente puros novedosos para el tratamiento de trastornos proliferativos.
ATE517892T1 (de) 2006-07-07 2011-08-15 Piramal Life Sciences Ltd Enantioselektive synthese pyrrolidinsubstituierter flavone
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
ATE538652T1 (de) 2007-05-15 2012-01-15 Piramal Life Sciences Ltd Synergistische pharmazeutische kombination für die behandlung von krebs
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US8906953B2 (en) 2010-02-26 2014-12-09 Piramal Enterprises Limited Pyrrolidine substitute flavones for the treatment of inflammatory disorders
CN101841463B (zh) * 2010-03-05 2012-05-16 清华大学 基于sctp的多路径并发传输方法
WO2012027438A1 (en) * 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
BR112013012313A2 (pt) 2010-11-19 2019-09-24 Piramal Entpr Ltd combinação farmacêutica de paclitaxel e um inibidor de cdk
US20130231347A1 (en) * 2010-11-19 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with braf inhibitor
WO2012123889A1 (en) * 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US20140142159A1 (en) 2011-06-24 2014-05-22 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
EP2802323B1 (en) 2012-01-13 2016-08-10 Piramal Enterprises Limited Pyrrolidine-substituted flavone derivatives for prevention or treatment of oral mucositis
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2014128523A1 (en) 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer

Also Published As

Publication number Publication date
JP6568060B2 (ja) 2019-08-28
IL243572A0 (en) 2016-02-29
WO2015004636A1 (en) 2015-01-15
JP2021001186A (ja) 2021-01-07
US20160136132A1 (en) 2016-05-19
CN111053768A (zh) 2020-04-24
JP2019206565A (ja) 2019-12-05
EP3019166B1 (en) 2019-05-08
DK3019166T3 (da) 2019-07-29
CN105530931A (zh) 2016-04-27
US20210393589A1 (en) 2021-12-23
TW202031253A (zh) 2020-09-01
AR096892A1 (es) 2016-02-03
EP3019166A1 (en) 2016-05-18
US20240165076A1 (en) 2024-05-23
ES2733929T3 (es) 2019-12-03
US12383530B2 (en) 2025-08-12
IL243572B (en) 2019-10-31
US11007174B2 (en) 2021-05-18
US11839591B2 (en) 2023-12-12
TW202233177A (zh) 2022-09-01
AU2014288857B2 (en) 2019-03-14
AU2014288857A1 (en) 2016-02-04
CA2917742A1 (en) 2015-01-15
CN111053768B (zh) 2023-12-12
TW202502325A (zh) 2025-01-16
CN105530931B (zh) 2019-11-08
JP2024037891A (ja) 2024-03-19
TW201534297A (zh) 2015-09-16
TWI839690B (zh) 2024-04-21
JP2022068335A (ja) 2022-05-09
US20190282544A1 (en) 2019-09-19
JP7799508B2 (ja) 2026-01-15
EP3019166A4 (en) 2017-04-19
TWI680760B (zh) 2020-01-01
CN117731786A (zh) 2024-03-22
JP2016525097A (ja) 2016-08-22

Similar Documents

Publication Publication Date Title
US12383530B2 (en) Pharmaceutical combination for the treatment of melanoma
US20200206188A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EA019571B1 (ru) Применение сульфизоксазола для лечения болезни альцгеймера
CN107249638A (zh) 阿匹莫德用于治疗肾癌
TW201242597A (en) A synergistic pharmaceutical combination for the treatment of pancreatic cancer
HK1224936B (en) A pharmaceutical combination for the treatment of melanoma
HK1224936A1 (en) A pharmaceutical combination for the treatment of melanoma
RU2687107C1 (ru) Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
HK40102341A (zh) 用於治疗黑素瘤的药物组合
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
EP2517707A1 (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
CA3220915A1 (en) Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
HK1170667A (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190710

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240717

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240717

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240718

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REFUND REQUEST RECEIVED

Effective date: 20241105